Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this review, the authors examined guidelines and literature on the non-operative treatment of gender dysphoria, highlighting the importance of personalized, multidisciplinary care, and noting that such treatment is generally safe and effective according to WPATH and Endocrine Society recommendations.

This study found that low serum testosterone and elevated serum oestrone in men with cirrhosis are associated with worse liver disease and adverse health outcomes, suggesting oestrone as a potential ill health marker.

This study found that finasteride effectively prevented testosterone-induced kidney stone formation in renal tubular cells by reducing COM crystal adhesion and crystallization.

This article reviews pharmacologic treatments for pattern hair loss and emphasizes integrating them with surgical and nonmedical options, but it does not present new clinical findings.

This review discusses the evaluation of hyperandrogenemia in women and hypogonadism in men across different life stages and presents biomarkers used for diagnosing male hypogonadism, reporting no new clinical results.

This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.

Finasteride can treat prostatic haematuria, but its use is controversial.

This study found that transdermal DHT treatment increased penile length in boys with 5α-reductase type 2 deficiency, but post-pubertal growth was limited and carried potential prostate complications.

In this study, researchers identified a new dominant mutation in Hairless mice, called Pied, resulting from a deletion in the Adam10 gene, which causes freckle-like skin pigmentation by inhibiting melanocyte expansion.

Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.

This study found that an earlier onset of androgenetic alopecia, especially in a frontal balding pattern, was significantly associated with an increased risk of prostate cancer among men at a Veterans Affairs Hospital.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

This review discusses the development and trials of finasteride for prostate cancer prevention, reporting reduced cancer prevalence but noting concerns about increased high-grade cancer incidence.

This review summarizes existing clinical guidelines for hormonal therapy in gender dysphoria, observing similarities in international practices and emphasizing the need for more evidence-based research, particularly on GnRH agonists for both trans women and men.

This study observed that integrating best practices for anabolic androgenic steroid users into Swiss primary care is feasible and well-accepted, though current doping laws hinder adequate medical care for this population.

This abstract explains that androgenetic alopecia, a common hair loss disorder influenced by genetics and hormones like dihydrotestosterone, has FDA-approved treatments including minoxidil, finasteride, and photolaser therapy, but its genetic basis and susceptibility to environmental factors remain complex.

This article reviews the pathophysiology, diagnosis, and treatment of androgenic alopecia but reports no new clinical findings.

This study found that oral contraceptives containing cyproterone acetate significantly improved the overall quality of life in polycystic ovary syndrome patients after 6 months compared to those containing levonorgestrel.

This study reported that both phlebotomy and oral contraceptive pills with cyproterone acetate effectively improved insulin resistance and androgenic profiles in women with PCOS, but OCs had more impact on regularizing menstrual cycles.

This study found that 11α-hydroxyprogesterone is a potent inhibitor of 11βHSD2 in vitro and may serve as a precursor to unique C11α-hydroxy steroids in prostate cancer tissue.

This study found that an oral testosterone formulation normalized serum testosterone levels and significantly reduced SHBG in men with experimentally induced hypogonadism after nine days of treatment, suggesting potential efficacy for testosterone deficiency.

This study found that a gene from hamster flank organs is indirectly regulated by androgens, despite lacking direct androgen responsive elements, indicating involvement of androgen-dependent transcription factors.

This narrative review reports that metformin, traditionally used for type 2 diabetes management, may offer therapeutic benefits for various skin disorders, such as acne, rosacea, and psoriasis, due to its anti-inflammatory and other beneficial properties, warranting further exploration in dermatology.

This study found that red ginseng oil (RXGIN) significantly improved lower urinary tract symptoms and some aspects of sexual function in men, with no serious adverse events reported.

In this review and meta-analysis, the authors concluded that 5α-reductase inhibitor therapy is not consistently associated with significant increases in serum testosterone levels in men.

This study found that the proposed Bayesian measurement-error-driven hidden Markov regression model effectively calibrated inflated covariate effect sizes in a community-based survey on androgenetic alopecia regardless of misclassification type.

This chapter reviews recent advances in 5α-reductase inhibitors for treating disorders mediated by dihydrotestosterone and reports no new clinical findings.

This review discusses available treatments for androgenetic alopecia in men, like finasteride and 5% minoxidil, and notes that hair growth results are unpredictable and often driven by industry-sponsored studies.

This study found that men with androgenetic alopecia at age 20 years may have a higher risk of developing aggressive prostate cancer, particularly advanced stage disease.